Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.
Bone is an organ commonly involved in spreading neoplastic disease, especially in multiple myeloma and carcinoma of the breast, prostate and lung. Skeletal stabilisation and pain relief are the main treatment goals in metastatic bone disease. Bisphosphonate treatment inhibits osseous breakdown and is well-established as the current standard therapy for reducing complications of neoplastic bone disease (e.g., pain, fractures and hypercalcaemia). Ibandronate is a third-generation bisphosphonate that has recently been approved for the treatment of bone metastases caused by breast cancer. The oral and intravenous formulations of ibandronate appear to have comparable efficacy. Ibandronate has also been shown to provide significant and sustained relief from metastatic bone pain over 2 years of treatment, improving patient functioning and quality of life. With a favourable long-term safety profile and the added convenience and flexibility offered by its efficacious oral formulation, ibandronate represents a new therapeutic option for metastatic bone disease management.
Pecherstorfer
Martin
M
Wilhelminenspital, First Department of Medicine and Oncology, Vienna, Austria. martin.pecherstorfer@wienkav.at
D001847:Bone Diseases / Q000188:drug therapy* / Q000209:etiology; D001859:Bone Neoplasms / Q000150:complications* / Q000556:secondary; D016723:Bone Remodeling / Q000187:drug effects*; D001862:Bone Resorption / Q000188:drug therapy* / Q000209:etiology; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D008297:Male
D004164:Diphosphonates; D000077557:Ibandronic Acid